A Cutting Edge Reply

A recent article 1 emphasized the increasing obesity within the American population, and the author criticized the Food and Drug Administration for not allowing wider use of olestra to reduce fat/caloric intake. This article crystallizes what is wrong with much health-related research today. It is a classic example of looking for a 'magic bullet' approach to a serious problem rather than making the comprehensive lifestyle changes required. I have been conducting a text-mining study on the disc

Written byRonald Kostoff
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

I have been conducting a text-mining study on the discipline of caloric restriction, focusing on the eclectic laboratory and clinical nonpathological experiences with controlled caloric restriction for health improvement, applied to all living species. Excluded are starvation, disease-caused caloric restriction, surgically-driven caloric restriction, and psychologically-driven caloric restriction (bulimia, anorexia). Preliminary results offer the following conclusions:

Thus, the hard laboratory and clinical evidence shows that caloric restriction can provide longevity and good health for small species, may provide such benefits to nonhuman primates, and may offer the potential to provide such benefits to humans. As far as I have been able to determine, controlled caloric restriction is the only regimen that has been demonstrated in the laboratory to increase life span, and therefore may be the foundational requirement for proper diet. In particular for humans, how can we make optimal use of these findings before all the conclusive laboratory and clinical ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies